LH (Labcorp Holdings Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by LH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | KERRII B ANDERSON | Director | Sell | — | — |
| 2026-08-12 | Adam H Schechter | President & CEO | Sell | — | — |
| 2026-08-06 | Amy B. Summy | EVP, Chief Marketing Officer | Sell | — | — |
| 2026-08-06 | Amy B. Summy | EVP, Chief Marketing Officer | Sell | — | — |
| 2026-08-05 | Peter J Wilkinson | SVP, Chief Accounting Officer | MIXED | — | — |
| 2026-07-06 | Bryan T Vaughn | EVP and President, Diagnostics | MIXED | — | — |
| 2026-07-06 | Kathryn W Kyle | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-06-10 | Kathryn W Kyle | EVP, Chief Legal Officer | Sell | — | — |
| 2026-05-13 | Adam H Schechter | President & CEO | Sell | — | — |
| 2026-03-30 | Megan D. Bailey | EVP, Pres, Central Labs & Intl | MIXED | — | — |
| 2026-03-30 | Kathryn W Kyle | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-03-30 | Jonathan C Meltzer | EVP, Operations | MIXED | — | — |
| 2026-03-30 | Akinbolade Oyegunwa | EVP, CIO & CTO | MIXED | — | — |
| 2026-03-30 | Amy B. Summy | EVP, Chief Marketing Officer | MIXED | — | — |
| 2026-03-30 | Vaart Sandra D van der | EVP, Corporate Affairs | MIXED | — | — |
| 2026-03-30 | Bryan T Vaughn | EVP, Diagnostics | MIXED | — | — |
| 2026-03-30 | Peter J Wilkinson | SVP, Chief Accounting Officer | MIXED | — | — |
| 2026-03-30 | Brian J Caveney | EVP, Pres of ED, CMO & CSO | MIXED | — | — |
| 2026-03-30 | Mark S Schroeder | EVP, Pres Diagnostics & COO | MIXED | — | — |
| 2026-03-30 | ANITA Z GRAHAM | EVP, CHRO | MIXED | — | — |
| 2026-03-30 | Adam H Schechter | President & CEO | MIXED | — | — |
| 2026-03-05 | Adam H Schechter | President & CEO | Sell | — | — |
| 2026-03-03 | Vaart Sandra D van der | EVP, Corporate Affairs | Sell | — | — |
| 2026-02-26 | Brian J Caveney | EVP, Pres of ED, CMO & CSO | Sell | — | — |
| 2026-02-23 | Peter J Wilkinson | SVP, Chief Accounting Officer | Sell | — | — |
| 2026-02-13 | KERRII B ANDERSON | Director | M | — | — |
| 2026-02-13 | Jeffrey A. Davis | Director | M | — | — |
| 2026-02-13 | Kirsten Marie Kliphouse | Director | M | — | — |
| 2026-02-13 | Garheng Kong | Director | M | — | — |
| 2026-02-13 | PETER M NEUPERT | Director | M | — | — |
| 2026-02-13 | Richelle P Parham | Director | M | — | — |
| 2026-02-13 | Kathryn E Wengel | Director | M | — | — |
| 2026-02-13 | Paul Rothman | Director | M | — | — |
| 2026-02-13 | Megan D. Bailey | EVP, Pres, Central Labs & Intl | MIXED | — | — |
| 2026-02-13 | Brian J Caveney | EVP, Pres of ED, CMO & CSO | MIXED | — | — |
| 2026-02-13 | ANITA Z GRAHAM | EVP, CHRO | MIXED | — | — |
| 2026-02-13 | Kathryn W Kyle | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-02-13 | Jonathan C Meltzer | EVP, Operations | MIXED | — | — |
| 2026-02-13 | Akinbolade Oyegunwa | EVP, CIO & CTO | MIXED | — | — |
| 2026-02-13 | Adam H Schechter | President & CEO | MIXED | — | — |
| 2026-02-13 | Mark S Schroeder | EVP, Pres Diagnostics & COO | MIXED | — | — |
| 2026-02-13 | Vaart Sandra D van der | EVP, Corporate Affairs | MIXED | — | — |
| 2026-02-13 | Bryan T Vaughn | EVP, Diagnostics | MIXED | — | — |
| 2026-02-13 | Julia Aijun Wang | Chief Financial Officer, EVP | MIXED | — | — |
| 2026-02-13 | Peter J Wilkinson | SVP, Chief Accounting Officer | MIXED | — | — |
| 2026-02-13 | Amy B. Summy | EVP, Chief Marketing Officer | MIXED | — | — |
| 2026-02-12 | KERRII B ANDERSON | Director | A | — | — |
| 2026-02-12 | Carulla Victor Bulto | Director | A | — | — |
| 2026-02-12 | Jeffrey A. Davis | Director | A | — | — |
| 2026-02-12 | Kirsten Marie Kliphouse | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 386,560 | — |
| — | President & CEO | 102,565 | — |
| — | EVP, Esoterix Business | 51,506 | — |
| — | Executive Vice President | 41,550 | — |
| — | EVP, Chief Scientific Officer | 38,592 | — |
| — | Director | 37,594 | — |
| — | EVP, Pres of ED, CMO & CSO | 35,368 | — |
| — | Chief Legal Officer, Secretary | 33,550 | — |
| — | EVP, Sales & Marketing | 31,352 | — |
| — | CMO, LabCorp Diagnostics | 30,423 | — |
| — | EVP & Chief Medical Officer | 29,090 | — |
| — | Chief Financial Officer, EVP | 28,146 | — |
| — | EVP,CEO of LabCorp Diagnostics | 27,300 | — |
| — | EVP | 25,955 | — |
| — | EVP | 23,196 | — |
| — | EVP, Chf Legal Offcr,Secretary | 21,193 | — |
| — | CEO, Covance Drug Development | 21,028 | — |
| — | Director | 20,029 | — |
| — | EVP, Special Advisor, Strategy | 20,005 | — |
| — | Director | 18,059 | — |
| — | Principal Accounting Officer | 17,974 | — |
| — | Director | 17,876 | — |
| — | EVP, Pres Diagnostics & COO | 15,777 | — |
| — | CEO, Covance Drug Development | 15,069 | — |
| — | EVP, Eastern Operations | 14,824 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LH quote page; the site-wide leaderboard is on the insider transactions hub.